CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes

Scandinavian Journal of Immunology

Volumn 54, Issue 3, 2001, Pages 249-264

  Gorrell, M D ^a,b   Gysbers, V ^a   McCaughan, G W ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BINDING PROTEIN; CD2 ANTIGEN; CD23 ANTIGEN; CELL MARKER; CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; PEPTIDE; PROTEIN TYROSINE KINASE; RECEPTOR; T LYMPHOCYTE RECEPTOR; TYROSINE;

ANTIGEN EXPRESSION; BINDING SITE; BIOLOGY; BLOOD LEVEL; CANCER; CELL MIGRATION; ENDOCRINOLOGY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; IMMUNOLOGY; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MEMORY CELL; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SOLUBILITY; STIMULATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION;

ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD26; CHEMOKINES; EXTRACELLULAR MATRIX; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0035723325     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00984.x     Document Type: Review

References (211)

1. A novel pathway of human T cell activation via a 103 kD T cell activation antigen
2. Triggering of cytotoxic T lymphocytes and NK cells via the Tp103 pathway is dependent on the expression of the T cell receptor/CD3 complex
3. Expression of the rat CD26 antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes
4. Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells
5. Functional role of CD26 on human B lymphocytes
6. Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry
7. Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: An analysis by tissue distribution, purification and N-terminal amino acid sequence
8. Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations
9. Distribution of adenosine deaminase complexing protein (ADCP) in human tissues
10. Molecular pathogenesis of liver disease: An approach to hepatic inflammation, cirrhosis and liver transplant tolerance
11. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody
12. Decreased serum dipeptidyl peptidase IV activity in major depression
13. Increased serum levels of dipeptidyl peptidase IV (CD26) in rats undergoing liver regeneration
14. Dipeptidyl peptidase IV from human serum: Purification, characterization, and N-terminal amino acid sequence
15. Molecular characterization of dipeptidyl peptidase activity in serum - Soluble CD26/ dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides
16. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation
17. Thymocyte costimulating antigen is CD26 (dipeptidyl-peptidase IV). Costimulation of granulocyte, macrophage, and T lineage cell proliferation via CD26
18. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation
19. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways
20. CD26 induces T-cell proliferation by tyrosine protein phosphorylation
21. The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes
22. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity
23. Enzymatic activity of CD26 (dipeptidylpeptidase IV) is not required for its signalling function in T cells
24. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production
25. 1F7, a novel cell surface molecule involved in helper function of CD4 cells
26. Influence of human T lymphocytes identified by antibodies to dipeptidyl peptidase IV on differentiation of human B lymphocytes stimulated with Staphylococcus aureus Cowan I and pokeweed mitogen
27. The structure and function of CD26 in the T cell immune response
28. CD26 workshop panel report
29. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV
30. Dipeptidyl peptidase IV, a kidney brush border serine protease
31. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides
32. Oligopeptidases, and the emergence of the prolyl oligopeptidase family
33. Post proline peptidases having DP IV like enzyme activity
34. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation normal T cell expressed and activated) by dipeptidyl peptidase IV (CD26)-mediated cleavage
35. CD26, let it cut or cut it down
36. Natural substrates of dipeptidyl peptidase IV
37. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78 beta into a most efficient monocyte attractant and CCR1 agonist
38. Good or evil: CD26 and HIV infection
39. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles
40. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): A possible mechanism for Tat's immunosuppressive activity
41. The N-Terminal structure of HIV-1 tat is required for suppression of CD26-dependent T cell growth
42. Dipeptidyl amino peptidase IV cytochemistry in circulating lymphocytes from HIV-I-seropositive subjects
43. Lymphocyte ectoenzyme activity compared in healthy persons and patients seropositive to or at high risk of HIV infection
44. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals
45. Decreased expression of the memory marker CD26 on both CD41 and CD81 T lymphocytes of HIV-infected subjects
46. CD26 expression correlates with entry, replication and cytopathicity of monocyto-tropic HIV-1 strains in a T-Cell line
47. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection
48. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage
49. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha
50. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase
51. Direct association of adenosine deaminase with a T cell activation antigen, CD26
52. Binding of adenosine deaminase to the lymphocyte surface via CD26
53. Expression of ecto-adenosine deaminase and CD26 in human T Cells triggered by the TCR-CD3 complex - Possible role of adenosine deaminase as costimulatory molecule
54. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response
55. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation
56. The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity
57. Cluster report: CD26
58. Distribution of adenosine deaminase-complexing protein in murine tissues
59. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver
60. Histochemical and biochemical distribution of dipeptidyl peptidase IV (DPP IV)
61. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases
62. Dipeptidyl peptidase IV in the immune system. Cytofluorometric evidence for induction of the enzyme on activated T lymphocytes
63. Dipeptidyl peptidase IV. A cell surface peptidase involved in regulating T cell growth
64. Interleukin 2 production by human T lymphocytes identified by antibodies to dipeptidyl peptidase IV
65. Cell surface characterization of T lymphocytes and allergen-specific T cell clones - Correlation of CD26 expression with T-H1 subsets
66. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes
67. 1F7 (CD26): A marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation
68. Characterization of a novel rat thymocyte costimulating antigen by the monoclonal antibody 1.3
69. Phenotypic characterization of CD4 ( ) T cells that exhibit a transendothelial migratory capacity
70. Antigen reactive memory T cells are defined by Ta1
71. Costimulation of CD41 and CD81 T cells through CD26: The ADA-binding epitope is not essential for complete signaling
72. Influence of CD26 and integrins on the antigen sensitivity of human memory T cells
73. Characterization of the 4C8 antigen involved in transendothelial migration of CD26 (hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers
74. Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis
75. Co-stimulation in T cell responses
76. Dipeptidyl-peptidase IV/CD26 on T cells: Analysis of an alternative T cell activation pathway
77. Anti-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1 phase of the cell cycle
78. FCR-mediated cross linking of Ta1 (CDW26) induced human T cell activation
79. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes
80. Cross-linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen-activated protein kinase
81. Early phosphorylation events induced by DPIV/CD26-specific inhibitors
82. Phenotypic and functional characterization of human T-lymphocytes defined by monoclonal against dipeptidyl peptidase IV (DPP IV)
83. Expression of CD26 (dipeptidyl peptidase IV) on memory and naive T lymphocytes
84. Induction of interleukin 2 (IL 2) and interferon-gamma and enhancement of IL 2 receptor expression by a CD26 monoclonal antibody
85. Cloning and functional expression of the T cell activation antigen CD26
86. Topology of the CD2-CD48 cell-adhesion molecule complex: Implications for antigen recognition by T cells
87. Temporal and subunit specific modulation of the Rel/NFkB transcription factors through CD28 costimulation
88. CD80, CD86 and CD40 provide accessory signals in a multi-step T-cell activation model
89. Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain
90. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes
91. The evolution of proteinase substrates with special reference to dipeptidylpeptidase IV
92. Rat dipeptidyl peptidase IV (DPP IV) exhibits endopeptidase activity with specificity for denatured fibrillar collagens
93. The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26
94. NF-kB activation by CD26 antigen is independent of dipeptidyl peptidase IV activity
95. The unique properties of dipeptidyl-peptidase IV (DPP IV / CD26) and the therapeutic potential of DPP IV inhibitors
96. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon - Characterization of glucagon degradation products and DPIV-resistant analogs
97. Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV)
98. A guardian angel. The involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence
99. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family
100. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness
101. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
102. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES. Possible mechanism for the switch from innate to acquired immune response
103. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro
104. Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system
105. Membrane-bound peptidases of lymphocytes: Functional implications
106. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) specifically suppress proliferation and modulate cytokine production of strongly CD26 expressing U937 cells
107. Zinc regulates DNA synthesis and IL-2, IL-6, and IL-10 production of PWM-stimulated PBMC and normalizes the peripheral cytokine concentration in chronic liver disease
108. Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells
109. In vitro immune responsiveness of rats lacking active dipeptidylpeptidase IV
110. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV
111. Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity
112. Molecular analysis of CD26-mediated signal transduction in T cells
113. Characterization of the adenosine deaminase-adenosine deaminase complexing protein binding reaction
114. 2 Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells
115. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes
116. Adenosine deaminase and immune function
117. Role of adenosine deaminase in lymphocyte proliferation
118. Effect of adenosine deaminase inhibition upon human lymphocyte blastogenesis
119. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death
120. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice
121. Hepatic dysfunction as a complication of adenosine deaminase deficiency
122. Human adenosine deaminase binding protein. Assay, purification, and properties
123. Presence of adenosine deaminase on the surface of mononuclear blood cells: Immunochemical localization using light and electron microscopy
124. Cell surface adenosine deaminase (ADA) and its complexing protein (ADCP) in human T-lymphoid cells
125. The sequence of the human genome
126. CD26/dipeptidyl peptidase IV does not work as an adenosine deaminase-binding protein in rat cells
127. The CP-I subunit of adenosine deaminase complexing protein from calf kidney is identical to human, mouse and rat dipeptidyl peptidase IV
128. Cell surface adenosine deaminase: Much more than an ectoenzyme
129. Extracellular purine metabolism
130. Ecto-enyzme and signaling functions of lymphocytes CD73
131. CD38: A new paradigm in lymphocyte activation and signal transduction
132. Biochemical characterization of CD26 (dipeptidyl peptidase IV): Functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies
133. The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV. The Arg142Gln mutation impairs binding to CD26 but does not cause immune deficiency
134. Human CD4 helper T cell activation: Functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family
135. Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen
136. Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix
137. Beta propellers. Structural rigidity and functional diversity
138. The kelch repeat superfamily of proteins: Propellers of cell function
139. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin
140. Dipeptidyl peptidase IV (CD26) is a receptor for streptokinase on rheumatoid synovial fibroblasts
141. The cysteine-rich region of dipeptidyl peptidase IV (CD26) is the collagen-binding site
142. Multiple antigenic determinants on type III collagen
143. Molecular analyses of human and rat dipeptidyl peptidase IV
144. A novel protease-docking function of integrin at invadopodia
145. Fibroblast activation protein. A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis
146. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8
147. Dipeptidyl peptidase IV (DPPIV/CD26): Biochemistry and control of cell-surface expression
148. Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity
149. Catalysis of serine oligopeptidases is controlled by a gating filter mechanism
150. Relating structure to function in the beta-propeller domain of dipeptidyl peptidase IV. Point mutations that ablate adenosine deaminase binding, antibody binding or DPP IV enzyme activity
151. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain
152. Prolyl oligopeptidase - An unusual beta-propeller domain regulates proteolysis
153. Demonstration of two molecular forms of dipeptidyl peptidase IV in normal human serum
154. Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation
155. Molecular cloning and sequence analysis of human dipeptidyl peptidase IV, a serine proteinase on the cell surface
156. Structural organization of the DP IV gene and its relationship with DPX and FAP-alpha transcripts
157. Genomic organisation, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene
158. Molecular dissection of the NH2-terminal signal/anchor sequence of rat dipeptidyl peptidase IV
159. Primary structure of rat liver dipeptidyl peptidase IV deduced from its cDNA and identification of the NH2-terminal signal sequence as the membrane-anchoring domain
160. Identification ofserine 624, aspartic acid 702, and histidine 734 as the catalytic triad residues of mouse dipeptidyl-peptidase IV (CD26). A member of a novel family of nonclassical serine hydrolases
161. CD26. Adenosine deaminase binding, immunoblotting and species cross reactivity examined using recombinant proteins
162. Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function
163. The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV (CD26) molecule
164. Principles of protein-protein interactions
165. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma
166. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers
167. New chromogenic substrates for X-prolyl dipeptidyl-aminopeptidase
168. X-prolyl dipeptidyl-aminopeptidase activity, with x-proline p-nitroanilides as substrates, in normal and pathological human sera
169. A novel form of dipeptidyl peptidase IV found in human serum - Isolation, characterization, and comparison with T lymphocyte membrane dipeptidyl peptidase IV (CD26)
170. Characterization of a soluble form of dipeptidyl peptidase IV from pig liver
171. Biosynthesis of intestinal microvillar proteins. Pulse-chase labelling studies on maltase-glucoamylase, aminopeptidase A and dipeptidyl peptidase IV
172. Proline specific endo- and exopeptidases
173. N-terminal amino-acid sequence of pig kidney dipeptidyl peptidase IV solubilized by autolysis
174. Proteins of the kidney microvillar membrane: The amphipathic form of dipeptidyl peptidase iv
175. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
176. Antibody-induced modulation of CD26 surface expression
177. Activation changes the spectrum but not the diversity of genes expressed by T cells
178. RNA expression in the early characterization of hepatotoxicants in wistar rats by high-density DNA microarrays
179. Transcript imaging of the development of human T helper cells using oligonucleotide arrays
180. Biosynthesis of intestinal microvillar proteins. Role of the Golgi complex and microtubules
181. Expression of enzymatically active rat dipeptidyl peptidase IV in Chinese hamster ovary cells after transfection
182. Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10-dimethyl-1,2-benzanthracene
183. Serum glycylproline p-nitroanilidase activity in blood cancers
184. Serum dipeptidyl peptidase (DPP) IV activities in oral cancer patients
185. Diagnostic value of the enzyme dipeptidyl peptidase IV (DP IV) in abdominal cancers
186. Increased activity of dipeptidyl peptidase IV in serum of hepatoma-bearing rats coincides with the loss of the enzyme from the hepatoma plasma membrane
187. Gamma-Glutamyltranspeptidase and dipeptidyl peptidase IV activity in the serum of normal and hepatoma-bearing chickens and in the plasma membranes from liver and hepatoma MC-29
188. The effects of CD26/ DPP IV-targeted therapy on acute allograft rejection
189. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset
190. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo
191. Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients
192. Lower serum dipeptidyl peptidase IV activity in treatment resistant major depression - Relationships with immune-inflammatory markers
193. The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen
194. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis
195. Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis
196. Dipeptidyl peptidase IV in patients with systemic lupus erythematosus
197. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome
198. Lowered Serum dipeptidyl peptidase IV activity in patients with anorexia and bulimia nervosa
199. An assay of dipeptidyl peptidase IV activity in human serum and serum of pregnant women with glycyl-l-proline-1-naphthylamide and other glycyl-l-proline-arylamides as substrates
200. Potentiation of the immune response in HIV-1 (1) individuals
201. In vivo and in vitro degradation of glucagon-like peptide-2 in humans
202. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice
203. Metabolism of glucagon by dipeptidyl peptidase IV (CD26)
204. Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor
205. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: Identification of MCP-2 (6-76) as a natural chemokine inhibitor
206. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3
207. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction
208. Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV
209. CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-gamma